February 8, 2025 Week in Review: Trade Wars, Earnings, and Labor Data
February 4, 2025 AI Ventures Soar as Trade Tensions Heat Up – Key Weekly Highlights
Nvidia Stock: Evaluating Competitive Risks Amid Growth Prospects
Apple: Valuation Concerns Persist Amid Fundamental Strength
February 5, 2025 Top 5 Coins for the Maximum Passive Income from Staking by 2024
January 21, 2025 Trading Stocks With AI: A Modern Approach
January 21, 2025 Bitcoin Is Great, but Here Are 3 Altcoins Worth Considering in 2025
January 1, 2025 Advanced Charting Tools For Traders
December 21, 2024 Why Is Trading Important?
Pfizer (PFE) Stock Forecast for 2025, 2026, 2027. Sell or Buy?
Updated: February 14, 2025 (09:56)
Sector: HealthcareThe share price of Pfizer Inc. (PFE) now
News Impact Analyzer
Full report
This Week
|
Bullish | Impact: 5 | News: 4 (4/0/0) |
Previous Week
|
Bullish | Impact: 1.9 | News: 9 (5/1/3) |
Two Weeks Ago
|
Na | Impact: Na | News: 4 (1/2/1) |
Three Weeks Ago
|
Bearish | Impact: 3 | News: 2 |
Analysts predictions
Full report
This Week
|
Bearish | Opinions: 2 |
Previous Week
|
Bearish | Opinions: 1 |
Two Weeks Ago
|
Neutral | Opinions: 1 |
Three Weeks Ago
|
Neutral | Opinions: Na |
Analyzing the Most Important PFE news

Pfizer’s Talzenna-Xtandi Combo Delivers Breakthrough in Prostate Cancer Study


Pfizer's Adcetris Secures Expanded Approval for Lymphoma Treatment


Pfizer Partners with Alloy for Cutting-Edge Antibody Discovery

Historical and forecast chart of Pfizer stock
The chart below shows the historical price of Pfizer stock and a prediction chart for the next month.
For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast,
and Weighted Average Best Forecast. Detailed values for the Pfizer stock price can be found in the table below.
Long-term forecasts by years.
Pfizer Inc. Analysts predictions review

Pfizer (PFE) faces persistent challenges, including declining revenues from pandemic-related products, increasing competition, and patent expirations on key drugs. While the $43 billion Seagen acquisition bolsters long-term oncology growth, it introduces near-term integration and profitability risks. Additionally, macroeconomic pressures like inflation and rising interest rates exacerbate cost and debt management issues. Despite a strong pipeline, the lack of immediate revenue drivers increases investor caution. These factors collectively signal downward pressure on the stock in the near term.

Pfizer: Evaluating the Risks That Shadow Growth Potential

Pfizer faces significant challenges stemming from declining revenues in its COVID-19 product portfolio. The reduction in demand for vaccines and antiviral treatments post-pandemic has created a substantial revenue gap, signaling a tougher revenue environment in the near term. The author underscores this revenue headwind as a critical factor applying downward pressure on valuation multiples.
In addition, Pfizer's ambitious $43 billion acquisition of Seagen presents mixed implications. While it bolsters long-term growth in oncology pipelines, the high cost and initial dilution bring considerable near-term integration risks that could weigh on profitability and cash flow generation.
Pipeline Concerns and Macroeconomic Pressures
Beyond acquisition-related risks, Pfizer’s reliance on its broader product pipeline and R&D productivity remains a concern. A failure to deliver innovative blockbuster drugs could magnify investor uncertainty, particularly as patents on key legacy drugs are set to expire in the coming years.
Lastly, macroeconomic headwinds, including rising interest rates and inflationary pressures, contribute further to bearish sentiment. These external pressures not only escalate input costs but also amplify refinancing challenges tied to the sizeable debt from recent acquisitions.

Pfizer: Weighing Valuation Concerns Amid Strategic Challenges

Pfizer's current valuation appears stretched, which could limit upside potential for its stock price in the near term. According to the author, the market may have overestimated the company’s ability to sustain its post-pandemic momentum, highlighting risks of a retracement.
Revenue headwinds are evident as pandemic-related tailwinds, such as COVID-19 vaccine sales, continue to wane while the company faces increased competition in its drug portfolio. The author emphasizes that Pfizer’s core growth prospects might not be sufficient to offset these declines without a robust pipeline or new breakthroughs.
Operational Challenges and Strategic Outlook
Pipeline execution remains a critical factor, as investors are closely watching developments in late-stage trials and potential regulatory approvals. While the author acknowledges Pfizer's R&D focus, delays or weaker-than-expected results would exacerbate investor concerns.
Macro factors, including inflationary pressures and rising interest rates, further compound profitability concerns. These external dynamics could weigh on Pfizer’s margins, dampening earnings visibility and amplifying near-term volatility in its stock price.

Pfizer Faces Pressure: Strong Q4 Performance Overshadowed by Weak Guidance and Patent Risks

Pfizer's Q4 financial results demonstrated a robust performance, supported by strong revenues and operational efficiency. However, these positive results have been largely overshadowed by forward-looking concerns highlighted in the company's updated guidance.
Key Drivers of Stock Performance
The company's revised forward guidance indicates significant revenue headwinds, likely tied to a cooling demand for pandemic-related products. This signals weakness in several core revenue streams, which could weigh on the stock in the near term.
Patent expiration concerns further amplify uncertainty, particularly around key blockbuster drugs nearing the end of their exclusivity period. The loss of market exclusivity is expected to severely curtail profit margins if new replacement products fail to adequately offset this gap.
While Pfizer has a robust pipeline of innovative therapies, the timeline for material contribution is considerably distant. Investors may remain cautious given the lack of immediate drivers to compensate for short-term revenue challenges.
Pfizer's valuation metrics stand out as a key driver for the investment thesis, with the company demonstrating compelling dividend yields and attractive price-to-earnings ratios relative to its peers. These attributes position Pfizer as a deserving candidate for income-focused strategies like Dogs of the Dow, especially as investors seek stable returns amid market uncertainties.
Pipeline and Innovation: The breadth of Pfizer's R&D pipeline and its progress in launching high-impact medications bolsters the long-term growth narrative. The ability to translate these efforts into commercial success could catalyze significant upside if key products meet or exceed market expectations.
The Dogs of the Dow strategy underscores Pfizer's potential as a top pick for 2025, leveraging its standing as a high-dividend-yield Dow Jones component. This approach plays into a value-focused perspective, which is particularly relevant as the market continues to price in economic headwinds and sector rotation impacts.
Pfizer's current dividend policy, while offering an attractive yield, lacks the same level of historical stability and growth reliability as some of its competitors. The author highlights this as a concern for income-focused investors because the company's dividend growth rate lags behind peers like Johnson & Johnson, which could weigh on its attractiveness as a defensive stock.
Recent performance challenges tied to post-pandemic revenue normalization, particularly in its COVID-19 product portfolio, create additional headwinds for Pfizer. These pressures are anticipated to impact the company's near-term earnings visibility, making it less appealing to growth-focused investors.
Strategic Positioning Limits Near-Term Momentum
Pfizer's dependence on new pipeline developments and strategic acquisitions to offset patent cliffs introduces a higher level of uncertainty to its outlook. According to the author, while these efforts could pay off in the long term, near-term execution risks could undermine investor confidence in the stock.
The comparative advantage enjoyed by competitors such as Johnson & Johnson in diversified business models further compounds Pfizer's challenges. The competitor's resilience across multiple segments not only strengthens relative valuation but also shifts attention away from Pfizer's more concentrated product strategy.
Pfizer’s near-term performance is underpinned by several critical drivers, including developments in its COVID-19 vaccine portfolio, patent challenges, and pipeline innovation. Analysts have emphasized the uncertainty surrounding revenue growth due to declining demand for Pfizer’s COVID-19 vaccine and antiviral treatments. This revenue deceleration could create headwinds, pressuring the stock in the short term.
Focus on Pipeline and Earnings Strategy
Efforts to offset declining COVID-19-related sales hinge on Pfizer’s ability to advance its non-COVID product pipeline. While the potential for new drug approvals offers long-term upside, immediate gains may be constrained as clinical development and commercialization timelines remain elongated. Moreover, patent expirations on cornerstone products such as Eliquis are a risk that could weigh on future profitability, necessitating proactive portfolio diversification.
On the earnings front, the company’s cost-cutting and share repurchase programs aim to bolster shareholder value amid top-line weakness. However, while these actions demonstrate management's commitment to financial discipline, they may not fully offset the structural revenue challenges in the near term.
Pfizer's growth trajectory appears to hinge on its efforts to diversify revenues and mitigate a post-pandemic lull, particularly as COVID-19-related product sales wane. The company's strategic shift towards expanding its pipeline in oncology, rare diseases, and mRNA technology signals a recalibration aimed at offsetting revenue dependence on its pandemic-era portfolio.
Management's focus on mergers and acquisitions (M&A) to bolster its drug portfolio and fortify long-term earnings potential is a pivotal factor. Recent high-profile acquisitions, such as the purchase of Seagen, reflect Pfizer's emphasis on acquiring capabilities in high-growth therapeutic areas, especially oncology, which is projected to be a significant value driver.
Pipeline Strength and Financial Dynamics
Clinical pipeline developments are expected to emerge as a critical short-term stock price driver. Key milestones for late-stage drug candidates and continued FDA approvals are poised to revive investor confidence, given the diminishing COVID-19 tailwinds.
On the financial side, near-term headwinds exist due to declining free cash flow from reduced COVID-19 vaccine revenues. However, robust capital allocation towards R&D and M&A, complemented by strong balance sheet fundamentals, positions Pfizer to weather this transitional phase effectively.
Comprehensive Analysis of Pfizer (PFE) Stock Market Performance
Our multifaceted analysis of Pfizer's stock market is grounded in the company's key news stories, insights from reputable analysts, as well as mathematical and technical evaluations. Taking into account assessments from each of these aspects in real-time helps us address the most crucial questions for investors in the most objective way possible:
- When should I take profit in Pfizer stock?
- When should I record a loss on Pfizer stock?
- What are analysts' forecasts for Pfizer stock?
- What is the future of Pfizer stock?
We forecast Pfizer stock performance using neural networks based on historical data on Pfizer stocks.
The Bright Future of PFE Stocks: An Unfolding Opportunity
In the world of high-stakes investing, few opportunities are as compelling as the case of Pfizer Inc. (NYSE:PFE). This pharmaceutical giant, standing on the threshold of its 176th year, has experienced a roller coaster in the stock market, touching a decade-low low of $26.93 per share. To understand the PFE stock forecast, it is crucial to investigate the events and factors poised to influence its performance.
The capability to predict PFE stock rates with high accuracy hinges significantly on analyzing the company’s strong fundamentals and upcoming market dynamics. Recently, the valuation of Pfizer has reached a depressed level, essentially providing a lucrative buying opportunity. Despite facing a decline in COVID-19 related product sales, Pfizer reported a commendable 7% operating sales growth in 2023, propelled by new product launches and the consistent growth of existing ones.
Factors Influencing PFE Stock Performance
Looking ahead, several core elements will play pivotal roles in shaping Pfizer’s stock trajectory. Firstly, the heavy influx of COVID-19 related revenue has bolstered Pfizer’s financial position, rendering the acquisition of Seagen—a leader in antibody-drug conjugate technology—a strategic masterstroke. This move positions Pfizer ahead in a competitive race within the pharma industry.
Moreover, while some of Pfizer’s key drugs are on the verge of hitting a patent cliff, the company’s robust and diverse pipeline promises not just to offset, but potentially eclipse, any potential shortfalls. Given these dynamics, forecasting a substantial upside for PFE stock seems not just optimistic but grounded in tangible facts and figures.
In conclusion, when contemplating the PFE stock buy or sell dilemma, it’s imperative to consider the projected EPS growth, the anticipated rise in EBITDA margins, and the transformative potential of Pfizer’s product pipeline. With an attractive dividend yield forecast of 6.19% for FY2024, the question isn’t so much ‘will PFE stock go up?’ but rather, ‘how high?’ As such, the PFE stock price target points towards an optimistic upward trend, making PFE stock an attractive proposition for both investors and analysts alike.
Pfizer Inc. stands tall as one of the global giants in the pharmaceutical industry, hailing from the United States. This powerhouse is behind a suite of well-known medications that have become household names. They’ve got Lipitor to keep cholesterol in check, Lyrica for nerve and muscle pain relief, Diflucan as an antifungal go-to, and Zithromax for bacterial infections.
There’s also the famed blue pill, Viagra, giving hope to those grappling with erectile dysfunction, while Celebrex battles arthritis and other forms of pain. Sermion comes to the aid of those with cognitive issues, Dostinex addresses hormonal imbalances, and Champix lends a hand to those determined to quit smoking.
Pfizer Inc. News influencing stock rates

As of now, Panda has combed through 19 news items directly related to PFE from the last 30 days. Out of these, 10 clearly showcase a bullish trend, while 5 display bearish tendencies, and 4 events are neutral.
The strength of the bullish trend outpaces the bearish sentiments by 2.57 times, indicating that the news backdrop is positively influencing the company’s stock price in the current outlook.
The news analyzed fell within the period from Jan 21, 2025, to Feb 13, 2025.
Pfizer's Padcev-Combo Boosts Survival in Urothelial Cancer


NYC Bird Flu Outbreak Forces Poultry Market Shutdowns


Bristol-Myers Squibb Falls Amid Tepid 2025 Outlook


Pfizer Accelerates Oncology Leadership with Seagen Integration, Sets Bold 2025 R&D Milestones


Pfizer Misses the Mark with 2025 Guidance Gap


Pfizer Posts Strong Q4 Growth Across Key Segments: Oncology +27.4%, Primary Care +26.5%


Pfizer Beats Q4 Earnings but Disappoints with FY2025 Forecast


Pfizer Surpasses Q4 Expectations with Strong Earnings and Revenue Growth


Pfizer Q4: Anticipated Revenue Surge Draws Market Attention


Pfizer's Braftovi Shows Positive Phase 3 Results in Colorectal Cancer Study


Pfizer daily forecast for a month
Date | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Feb 16 | 26.62 | 26.19 | 26.78 | 2.26 |
Feb 17 | 26.57 | 26.15 | 27.10 | 3.63 |
Feb 18 | 26.94 | 26.55 | 27.56 | 3.81 |
Feb 19 | 26.39 | 26.09 | 26.97 | 3.37 |
Feb 20 | 26.66 | 26.36 | 27.00 | 2.43 |
Feb 21 | 26.45 | 25.88 | 26.99 | 4.26 |
Feb 22 | 26.09 | 25.60 | 26.64 | 4.07 |
Feb 23 | 26.35 | 25.81 | 26.62 | 3.15 |
Feb 24 | 26.35 | 26.17 | 26.81 | 2.45 |
Feb 25 | 26.04 | 25.56 | 26.47 | 3.54 |
Feb 26 | 26.05 | 25.48 | 26.46 | 3.83 |
Feb 27 | 26.22 | 25.73 | 26.51 | 3.03 |
Feb 28 | 26.34 | 26.04 | 26.91 | 3.34 |
Mar 01 | 26.79 | 26.21 | 27.22 | 3.86 |
Mar 02 | 26.57 | 25.99 | 27.10 | 4.26 |
Mar 03 | 27.07 | 26.91 | 27.35 | 1.63 |
Mar 04 | 27.23 | 26.59 | 27.76 | 4.39 |
Mar 05 | 27.89 | 27.44 | 28.52 | 3.96 |
Mar 06 | 28.00 | 27.62 | 28.51 | 3.22 |
Mar 07 | 27.56 | 27.29 | 28.17 | 3.24 |
Mar 08 | 27.73 | 27.07 | 28.02 | 3.50 |
Mar 09 | 26.96 | 26.38 | 27.26 | 3.34 |
Mar 10 | 27.25 | 27.03 | 27.82 | 2.93 |
Mar 11 | 27.21 | 26.71 | 27.54 | 3.09 |
Mar 12 | 27.40 | 27.16 | 27.90 | 2.72 |
Mar 13 | 27.79 | 27.25 | 28.00 | 2.75 |
Mar 14 | 27.70 | 27.30 | 28.04 | 2.71 |
Mar 15 | 27.14 | 26.89 | 27.40 | 1.88 |
Mar 16 | 27.18 | 26.96 | 27.59 | 2.36 |
Mar 17 | 27.18 | 26.87 | 27.45 | 2.19 |
Pfizer Daily Price Targets
Pfizer Stock Forecast 02-16-2025.
Forecast target price for 02-16-2025: $26.62.
Positive dynamics for Pfizer shares will prevail with possible volatility of 2.207%.
Pessimistic target level: 26.19
Optimistic target level: 26.78
Pfizer Stock Forecast 02-17-2025.
Forecast target price for 02-17-2025: $26.57.
Negative dynamics for Pfizer shares will prevail with possible volatility of 3.500%.
Pessimistic target level: 26.15
Optimistic target level: 27.10
Pfizer Stock Forecast 02-18-2025.
Forecast target price for 02-18-2025: $26.94.
Positive dynamics for Pfizer shares will prevail with possible volatility of 3.667%.
Pessimistic target level: 26.55
Optimistic target level: 27.56
Pfizer Stock Forecast 02-19-2025.
Forecast target price for 02-19-2025: $26.39.
Negative dynamics for Pfizer shares will prevail with possible volatility of 3.259%.
Pessimistic target level: 26.09
Optimistic target level: 26.97
Pfizer Stock Forecast 02-20-2025.
Forecast target price for 02-20-2025: $26.66.
Positive dynamics for Pfizer shares will prevail with possible volatility of 2.370%.
Pessimistic target level: 26.36
Optimistic target level: 27.00
Pfizer Stock Forecast 02-21-2025.
Forecast target price for 02-21-2025: $26.45.
Negative dynamics for Pfizer shares will prevail with possible volatility of 4.088%.
Pessimistic target level: 25.88
Optimistic target level: 26.99
PFE (PFE) Monthly Stock Prediction for 2025
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Mar. | 25.17 | 24.20 | 26.80 | 9.72 |
Apr. | 27.14 | 25.53 | 27.83 | 8.25 |
May. | 27.90 | 26.24 | 28.78 | 8.81 |
Jun. | 26.75 | 25.88 | 27.37 | 5.45 |
Jul. | 24.65 | 22.94 | 25.96 | 11.62 |
Aug. | 23.81 | 23.12 | 25.12 | 7.93 |
Sep. | 22.84 | 22.06 | 23.85 | 7.50 |
Oct. | 21.82 | 20.89 | 22.54 | 7.32 |
Nov. | 21.07 | 19.69 | 22.28 | 11.66 |
Dec. | 20.18 | 19.31 | 21.50 | 10.22 |
Pfizer forecast for this year
Pfizer Stock Prediction for Mar 2025
An downtrend is forecast for this month with an optimal target price of $25.172. Pessimistic: $24.20. Optimistic: $26.80
Pfizer Stock Prediction for Apr 2025
An uptrend is forecast for this month with an optimal target price of $27.143. Pessimistic: $25.53. Optimistic: $27.83
Pfizer Stock Prediction for May 2025
An uptrend is forecast for this month with an optimal target price of $27.9003. Pessimistic: $26.24. Optimistic: $28.78
Pfizer Stock Prediction for Jun 2025
An downtrend is forecast for this month with an optimal target price of $26.7452. Pessimistic: $25.88. Optimistic: $27.37
Pfizer Stock Prediction for Jul 2025
An downtrend is forecast for this month with an optimal target price of $24.651. Pessimistic: $22.94. Optimistic: $25.96
Pfizer Stock Prediction for Aug 2025
An downtrend is forecast for this month with an optimal target price of $23.808. Pessimistic: $23.12. Optimistic: $25.12
Pfizer Stock Prediction for Sep 2025
An downtrend is forecast for this month with an optimal target price of $22.8438. Pessimistic: $22.06. Optimistic: $23.85
Pfizer Stock Prediction for Oct 2025
An downtrend is forecast for this month with an optimal target price of $21.8158. Pessimistic: $20.89. Optimistic: $22.54
Pfizer Stock Prediction for Nov 2025
An downtrend is forecast for this month with an optimal target price of $21.0697. Pessimistic: $19.69. Optimistic: $22.28
Pfizer Stock Prediction for Dec 2025
An downtrend is forecast for this month with an optimal target price of $20.1784. Pessimistic: $19.31. Optimistic: $21.50
Pfizer (PFE) Monthly Stock Prediction for 2026
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 19.47 | 18.68 | 20.59 | 9.28 |
Feb | 20.22 | 18.77 | 21.55 | 12.92 |
Mar | 21.57 | 21.03 | 22.13 | 5.00 |
Apr | 22.11 | 20.54 | 23.29 | 11.79 |
May | 23.23 | 21.60 | 24.55 | 12.01 |
Jun | 24.65 | 23.96 | 25.52 | 6.09 |
Jul | 25.36 | 24.08 | 26.71 | 9.83 |
Aug | 26.66 | 25.63 | 27.72 | 7.53 |
Sep | 25.94 | 25.17 | 27.02 | 6.83 |
Oct | 26.34 | 24.82 | 28.07 | 11.57 |
Nov | 24.02 | 23.17 | 25.66 | 9.69 |
Dec | 24.40 | 23.06 | 25.46 | 9.40 |
Pfizer (PFE) Monthly Stock Prediction for 2027
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 24.91 | 23.45 | 26.19 | 10.44 |
Feb | 26.77 | 26.29 | 27.83 | 5.54 |
Mar | 27.54 | 26.97 | 28.38 | 4.98 |
Apr | 27.76 | 26.84 | 29.21 | 8.13 |
May | 29.34 | 28.47 | 30.05 | 5.27 |
Jun | 27.28 | 25.49 | 28.60 | 10.90 |
Jul | 25.63 | 24.50 | 26.37 | 7.09 |
Aug | 26.65 | 25.47 | 28.04 | 9.15 |
Sep | 26.22 | 24.92 | 27.80 | 10.36 |
Oct | 26.97 | 26.46 | 28.67 | 7.70 |
Nov | 26.83 | 26.01 | 28.66 | 9.27 |
Dec | 26.15 | 24.46 | 27.75 | 11.87 |
Pfizer information and performance
235 E 42ND ST, NEW YORK, NY, US
Market capitalization of the Pfizer Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of PFE shares in the company outstanding by the market price of one share.
EBITDA of Pfizer is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
Pfizer (PFE) stock dividend
Pfizer last paid dividends on 01/24/2025. The next scheduled payment will be on 03/07/2025. The amount of dividends is $0 per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.
Last Split Date: 01/01/1970
Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.
For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.
FAQ (Frequently Asked Questions about Pfizer Stock)
Should I Buy Pfizer Shares in 2025 year?
Does Pfizer pay dividends?
Which economic sector do Pfizer's shares belong to?
Which other securities belong to the same sector as Pfizer's shares?
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.